Curated News:

Medical Meetings

Add to Favorites Subscribe Share
fbshare-Medical Meetings

Showing results

4150 of 3688
mmc-logo.gif
  • Embargo expired:
    3-Jun-2019 7:30 AM EDT

Article ID: 713754

2 Mayo Clinic studies examine discrimination, bias in health care organizations

Mayo Clinic

Two studies that explore types of discrimination and gender bias in health care organizations will be presented by Mayo Clinic researchers at the American Society of Clinical Oncology annual meeting in Chicago.

Released:
31-May-2019 12:00 PM EDT
mmc-logo.gif
  • Embargo expired:
    3-Jun-2019 7:30 AM EDT

Article ID: 713757

Study: Genetic information can encourage women to accept preventive cancer treatment

Mayo Clinic

Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by aromatase inhibitors. Nevertheless, women at high risk of breast cancer have a low acceptance of preventive medicine. A new study by Mayo Clinic and collaborators at the University of Manitoba and CancerCare Manitoba suggests that when women at high risk are presented with personalized genetic information, they're more likely to take preventative medications to reduce their chance of developing breast cancer. The research involved a new blood test developed by Mayo Clinic to identify women at higher genetic risk for developing breast cancer.

Released:
31-May-2019 12:00 PM EDT
Newswise: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

Article ID: 713794

Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

University of Texas M. D. Anderson Cancer Center

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.

Released:
3-Jun-2019 4:55 AM EDT
Newswise: ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

Article ID: 713799

ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

Roswell Park Comprehensive Cancer Center

With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.

Released:
3-Jun-2019 4:50 AM EDT
  • Embargo expired:
    2-Jun-2019 7:30 AM EDT

Article ID: 713589

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Dana-Farber Cancer Institute

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.

Released:
2-Jun-2019 6:30 AM EDT
mmc-logo.gif
  • Embargo expired:
    2-Jun-2019 7:30 AM EDT

Article ID: 713755

Study finds drug therapy can delay onset of myeloma symptoms

Mayo Clinic

The largest randomized trial involving smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of myeloma symptoms, according to Mayo Clinic researchers. The study was conducted by the Eastern Cooperative Oncology Group and funded by the National Cancer Institute.

Released:
31-May-2019 12:00 PM EDT
Newswise: Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer
  • Embargo expired:
    1-Jun-2019 7:30 AM EDT

Article ID: 713709

Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer

University of Texas M. D. Anderson Cancer Center

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Released:
31-May-2019 7:30 AM EDT
UNC-Health-Care_RGBcopy.jpg

Article ID: 713788

Study: Men with Early-Stage Prostate Cancer Who Choose Active Surveillance Often Don’t Follow Monitoring Guidelines

University of North Carolina Health Care System

Researchers found just 15 percent of a group of men with early-stage prostate cancer received biopsies and other tests according to active surveillance guidelines from the National Comprehensive Cancer Network.

Released:
31-May-2019 4:30 PM EDT
Newswise: Rutgers Cancer Institute of New Jersey Physician-Scientists Present Findings on Immunotherapy and Other Clinical Research at National Meeting

Article ID: 713585

Rutgers Cancer Institute of New Jersey Physician-Scientists Present Findings on Immunotherapy and Other Clinical Research at National Meeting

Rutgers Cancer Institute of New Jersey

Findings from Rutgers Cancer Institute of New Jersey focused on immunotherapy will be featured at the 2019 American Society of Clinical Oncology Annual Meeting being held in Chicago tomorrow through Tuesday.

Released:
30-May-2019 8:00 AM EDT

Showing results

4150 of 3688

Chat now!